Qingting Huang

Qingting Huang

Auto-generated profile, based on publicly available information

Qingting Huang

Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center Fudan University Cancer Hospital Shanghai China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
QHQingting Huang
Qingting Huang
JHJiyi Hu
Jiyi Hu
LCLi Chen
Li Chen
WLWanzun Lin
Wanzun Lin
JYJing Yang
Jing Yang
LKLin Kong
Lin Kong
Carbon ion radiotherapy (CIRT) may yield satisfactory clinical outcomes for patients who are resistant to radiotherapy. However, the therapeutic impact of carbon ions is still limited in certain recurring or refractory tumors. Therefore, we aimed to evaluate the synergistic anti-tumor effects of immune checkpoint inhibitors (ICIs) in combination with CIRT. We then explored the involvement of ferroptosis in a preliminary investigation. A tumor-bearing mouse model was established, and mice were inoculated subcutaneously with B16-OVA cells into the flanks of both hind legs. Mice were assigned to four groups to receive CIRT, ICIs, or combined treatment. Thereafter, we conducted transcriptome sequencing (RNA-seq), bioinformatics analysis, and various immune-related experiments on the available tumor tissues to investigate differences in the synergistic anticancer effects and potential mechanisms across the groups. The combination therapies significantly improved the survival of mice and inhibited tumor growth, both at local and distant sites. Based on bioinformatics and RNA-seq data, immune-related pathways and genes, immune cell infiltration, and the production of cytokines and chemokines were the most enhanced in the combined treatment group compared to other groups. Finally, we identified a potential role for ferroptosis in the development of local anti-tumor synergy during CIRT combination treatment. In conclusion, this study showed that CIRT and ICIs can enhance the anti-tumor immune effects. We also proposed that ferroptosis may induce anti-tumor effects in CIRT combination therapy, offering a unique perspective on its ability to enhance immunotherapy responses.

17 February 2016 in Oncology Letters
Verified
Journal Article
Open access
PDF file
SQSufang Qiu
Sufang Qiu
QHQingting Huang
Qingting Huang
LHLingling Huang
Lingling Huang
JLJinyong Lin
Jinyong Lin
JLJun Lu
Jun Lu
RCRong Chen
Rong Chen
The present study aimed to evaluate a label-free tissue test for the detection of nasopharyngeal carcinoma (NPC) at early and advanced stages using Raman spectroscopy (RS). RS measurements were performed to acquire high quality Raman spectra on two groups of tissue samples: One group consists of 30 NPC patients at the early stages (I–II), and the other group is 46 NPC patients at the advanced stages (III–IV). Tentative assignment of Raman bands showed specific biomolecular changes associated with cancer development. Furthermore, effective diagnostic algorithms based on principal components analysis (PCA) and linear discriminant analysis (LDA) were applied for distinguishing Raman spectra of nasopharyngeal tissues from different stages, yielding a diagnostic sensitivity of 70% and a specificity of 78%. This exploratory work suggests that RS in conjunction with the PCA-LDA algorithms provides good diagnostic ability for the early and the advanced staged NPC tissues, and RS has enormous potential for the non-invasive detection of early and advanced stage NPC.

11 April 2023 in Cancer Medicine
Verified
Journal Article
Open access
QHQingting Huang
Qingting Huang
JHJiyi Hu
Jiyi Hu
WHWeixu Hu
Weixu Hu
JGJing Gao
Jing Gao
JYJing Yang
Jing Yang
LKLin Kong
Lin Kong
Purpose Further improvement in clinical outcomes is needed for patients with head and neck squamous cell carcinoma (HNSCC), as there is typically a poor prognosis at diagnosis. This study aimed to report the preliminary therapeutic outcomes and side effects in patients with HNSCC receiving particle beam radiotherapy (PBRT), owing to the physical and biological advantages of this approach.Methods We retrospectively analyzed 68 patients with newly diagnosed HNSCC who received PBRT at the Shanghai Proton and Heavy Ion Center (SPHIC) between August 2015 and December 2020. The Kaplan-Meier approach was used to determine overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS). Common Terminology Criteria for Adverse Events (CTCAE) 4.03 was also used to grade acute and late toxicities.Results With a median follow-up time of 24.5 months (range, 3-65), the 3-year OS, DSS, PFS, LRFS, RRFS, and DMFS rates for the entire cohort were 79.0%, 84.7%, 67.9%, 83.5%, 83.3%, and 96.1%, respectively. Univariate and multivariate analyses showed that N category was a significant predictor of OS, PFS, and RRFS. In terms of acute toxicities, two patients demonstrated severe mucositis or dysphagia, and two patients also displayed a late toxicity of significant mucosal necrosis.Conclusion These findings suggest that PBRT can provide patients with HNSCC with a promising therapeutic benefit and manageable toxicity. Prospective evaluation of clinical outcomes with PBRT for HNSCC is warranted, with an emphasis on clinical effectiveness as well as adverse effects and patient quality of life.

11 January 2024 in Cancer Medicine
Verified
Journal Article
Open access
JHJiyi Hu
Jiyi Hu
QHQingting Huang
Qingting Huang
WHWeixu Hu
Weixu Hu
JGJing Gao
Jing Gao
JYJing Yang
Jing Yang
LKLin Kong
Lin Kong
Purpose: Management of locoregionally recurrent nasopharyngeal carcinoma (LR NPC) is difficult. Although carbon‐ion radiation therapy (CIRT) could substantially improve the overall survival (OS) of those patients, around 40% of the patients may still develop local failure. Further improvement of the disease control is necessary. Immunotherapy, such as immune checkpoint inhibitors (ICIs) becomes a promising antitumor treatment. The role of ICIs was proved in head and neck cancers including recurrent/metastatic NPC. Preclinical studies indicated potential synergistic effects between radiation therapy and ICIs. Therefore, we conduct a randomized phase 2 trial to evaluate the efficacy and safety of camrelizumab, an anti‐PD‐1 monoclonal antibody, along with CIRT in patients with LR NPC.Methods: Patients will be randomly assigned at 1:1 to receive either standard CIRT with 63 Gy (relatively biological effectiveness, [RBE]) in 21 fractions, or standard CIRT plus concurrent camrelizumab. Camrelizumab will be administered intravenously with a dose of 200 mg, every 2 week, for a maximum of 1 year. We estimate addition of camrelizumab will improve the 2‐year progression‐free survival (PFS) from 45% to 60%. A total of 146 patients (with a 5% lost to follow‐up rate) is required to yield a type I error of 0.2, and a power of 0.8.Results and Conclusion: The results of the trial may shed insights on the combined therapy with ICIs and CIRT.

1 October 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JLJiade Lu
Jiade Lu
JHJiyi Hu
Jiyi Hu
JGJing Gao
Jing Gao
XGXiyin Guan
Xiyin Guan
WHWeixu Hu
Weixu Hu
LKLin Kong
Lin Kong